Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Zavadak

Dermatology Lebanon, PA Medical Doctor

NPI 1598745747 CMS profile 299590

923 Russell Dr, Lebanon, PA 17042

Open in the dashboard

General payments

$13,921

912 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Zavadak of Lebanon, PA is reported in the CMS Open Payments database as having received $13,921 across 912 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,716 144
2024 General $3,638 203
2023 General $2,559 166
2022 General $2,589 203
2021 General $1,119 108
2020 General $718 51
2019 General $583 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Zavadak
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Daniel Zavadak were reported at $2,716. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Daniel Zavadak Dermatology median Middle half National median
2019 $583 $454 $129–$1,240 $163
2020 $718 $235 $81–$756 $114
2021 $1,119 $377 $108–$1,108 $132
2022 $2,589 $514 $143–$1,391 $149
2023 $2,559 $607 $159–$1,674 $160
2024 $3,638 $751 $204–$1,903 $164
2025 $2,716 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,464 256 payments
  2. Janssen Biotech, Inc. $2,344 265 payments
  3. UCB, Inc. $1,139 55 payments
  4. Lilly USA, LLC $884 54 payments
  5. Genzyme Corporation $829 32 payments
  6. Amgen Inc. $798 51 payments
  7. Regeneron Healthcare Solutions, Inc. $786 28 payments
  8. E.R. Squibb & Sons, L.L.C. $448 27 payments
  9. Novartis Pharmaceuticals Corporation $436 27 payments
  10. Pfizer Inc. $389 29 payments
  11. Other $1,405 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,790 908 payments
  2. Education $131 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $2,278 107 payments
  2. TREMFYA $2,031 228 payments
  3. SKYRIZI $1,380 110 payments
  4. DUPIXENT Immunology $1,064 41 payments
  5. Otezla $798 51 payments
  6. HUMIRA $727 48 payments
  7. TALTZ $717 47 payments
  8. Bimzelx $582 25 payments
  9. DUPIXENT Inflammation And Immunology $566 21 payments
  10. Cimzia $557 30 payments
  11. Other $5,278 389 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,657

Median for Dermatology: 534

Drug cost

$1,377,408

Median for Dermatology: $67,151

Branded share of claims

26.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 16 $330,435
Taltz Autoinjector Ixekizumab Brand 37 $253,023
Cosentyx Sensoready (2 Pens) Secukinumab Brand 28 $203,302
Dupixent Pen Dupilumab Brand 33 $155,482
Otezla Apremilast Brand 23 $121,652
Rinvoq Upadacitinib Brand 20 $120,390
Cyltezo(Cf) Pen Adalimumab-Adbm Brand 15 $107,761
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 119 $35,741
Acitretin Generic 16 $6,044
Clobetasol Propionate Generic 128 $5,342

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$205,181

Of which drugs: $31

Medicare patients

1,258

Average age 76

Services billed

3,114

650 women, 608 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 49%
Ischemic heart disease 27%
Diabetes 26%
Chronic kidney disease 24%
Osteoporosis 20%
Atrial fibrillation 18%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 41 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$612 — —
RINVOQ
$588 20 —
SKYRIZI
$374 16 —
DUPIXENT
$338 33 —
Otezla
$322 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

912 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record